PRESS RELEASE
29 August 2023

Genesis Therapeutics Closes Oversubscribed $200 Million Series B

CL
Cooley LLP

Contributor

Cooley LLP logo
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law. Cooley has nearly 1,400 lawyers across 18 offices in the United States, Asia and Europe, and a total workforce of more than 3,000.
Cooley advised Andreessen Horowitz (a16z) Bio + Health Tech Investments, an a16z fund with a focus on biotechnology and healthcare technology, in connection with Genesis Therapeutics’ oversubscribed $200 million Series B financing.
United States

Palo Alto – August 21, 2023 – Cooley advised Andreessen Horowitz (a16z) Bio + Health Tech Investments, an a16z fund with a focus on biotechnology and healthcare technology, in connection with Genesis Therapeutics' oversubscribed $200 million Series B financing. Lawyers Josh Seidenfeld and Thomas Heiser led the Cooley team advising a16z Bio + Health.

Genesis will use proceeds from the round to advance its existing, wholly owned pipeline of artificial intelligence-enabled programs into clinical development, invest in continued development of novel and state-of-the-art generative and predictive AI methods, and expand its pipeline.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has nearly 1,400 lawyers across 18 offices in the United States, Asia and Europe, and a total workforce of more than 3,000.

Contributor

Cooley LLP logo
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law. Cooley has nearly 1,400 lawyers across 18 offices in the United States, Asia and Europe, and a total workforce of more than 3,000.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More